vs
纽约梅隆银行（BK）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
纽约梅隆银行的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），纽约梅隆银行净利率更高（108.5% vs 12.7%，领先95.8%），纽约梅隆银行同比增速更快（12.7% vs 5.9%），纽约梅隆银行自由现金流更多（$4.7B vs $161.8M），过去两年纽约梅隆银行的营收复合增速更高（13.8% vs 9.0%）
纽约梅隆银行是总部位于美国纽约的全球性金融服务机构，2007年7月由纽约银行与梅隆金融公司合并组建而成，业务覆盖全球众多市场，为机构、企业及个人客户提供专业金融服务，在资产管理、证券服务等领域拥有领先的行业地位。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BK vs RVTY — 直观对比
营收规模更大
BK
是对方的1.7倍
$772.1M
营收增速更快
BK
高出6.9%
5.9%
净利率更高
BK
高出95.8%
12.7%
自由现金流更多
BK
多$4.6B
$161.8M
两年增速更快
BK
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $1.5B | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | 108.5% | 12.7% |
| 营收同比 | 12.7% | 5.9% |
| 净利润同比 | 26.5% | 3.9% |
| 每股收益（稀释后） | $2.01 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BKRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.0B | $684.0M | ||
| Q2 24 | $1.0B | $691.7M | ||
| Q1 24 | $1.0B | $649.9M |
净利润BKRVTY
| Q4 25 | $1.5B | $98.4M | ||
| Q3 25 | $1.4B | $46.7M | ||
| Q2 25 | $1.4B | $53.9M | ||
| Q1 25 | $1.2B | $42.2M | ||
| Q4 24 | $1.2B | $94.6M | ||
| Q3 24 | $1.2B | $94.4M | ||
| Q2 24 | $1.2B | $55.4M | ||
| Q1 24 | $1.0B | $26.0M |
毛利率BKRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率BKRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 12.6% | ||
| Q1 25 | — | 10.9% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | — | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率BKRVTY
| Q4 25 | 108.5% | 12.7% | ||
| Q3 25 | 116.9% | 6.7% | ||
| Q2 25 | 118.3% | 7.5% | ||
| Q1 25 | 105.3% | 6.4% | ||
| Q4 24 | 96.7% | 13.0% | ||
| Q3 24 | 112.8% | 13.8% | ||
| Q2 24 | 113.4% | 8.0% | ||
| Q1 24 | 98.6% | 4.0% |
每股收益（稀释后）BKRVTY
| Q4 25 | $2.01 | $0.86 | ||
| Q3 25 | $1.88 | $0.40 | ||
| Q2 25 | $1.93 | $0.46 | ||
| Q1 25 | $1.58 | $0.35 | ||
| Q4 24 | $1.53 | $0.77 | ||
| Q3 24 | $1.50 | $0.77 | ||
| Q2 24 | $1.52 | $0.45 | ||
| Q1 24 | $1.25 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.1B | $919.9M |
| 总债务越低越好 | $31.9B | — |
| 股东权益账面价值 | $44.3B | $7.3B |
| 总资产 | $472.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
现金及短期投资BKRVTY
| Q4 25 | $5.1B | $919.9M | ||
| Q3 25 | $5.1B | $931.4M | ||
| Q2 25 | $5.7B | $991.8M | ||
| Q1 25 | $5.4B | $1.1B | ||
| Q4 24 | $4.2B | $1.2B | ||
| Q3 24 | $6.2B | $1.2B | ||
| Q2 24 | $5.3B | $2.0B | ||
| Q1 24 | $5.3B | $1.7B |
总债务BKRVTY
| Q4 25 | $31.9B | — | ||
| Q3 25 | $32.3B | — | ||
| Q2 25 | $33.4B | — | ||
| Q1 25 | $30.9B | — | ||
| Q4 24 | $30.9B | — | ||
| Q3 24 | $33.2B | — | ||
| Q2 24 | $30.9B | — | ||
| Q1 24 | $32.4B | — |
股东权益BKRVTY
| Q4 25 | $44.3B | $7.3B | ||
| Q3 25 | $43.9B | $7.4B | ||
| Q2 25 | $44.0B | $7.6B | ||
| Q1 25 | $43.1B | $7.6B | ||
| Q4 24 | $41.3B | $7.7B | ||
| Q3 24 | $42.0B | $7.9B | ||
| Q2 24 | $40.8B | $7.9B | ||
| Q1 24 | $40.6B | $7.8B |
总资产BKRVTY
| Q4 25 | $472.3B | $12.2B | ||
| Q3 25 | $455.3B | $12.1B | ||
| Q2 25 | $485.8B | $12.4B | ||
| Q1 25 | $440.7B | $12.4B | ||
| Q4 24 | $416.1B | $12.4B | ||
| Q3 24 | $427.5B | $12.8B | ||
| Q2 24 | $428.5B | $13.4B | ||
| Q1 24 | $434.7B | $13.4B |
负债/权益比BKRVTY
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.76× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | 0.79× | — | ||
| Q2 24 | 0.76× | — | ||
| Q1 24 | 0.80× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $4.7B | $161.8M |
| 自由现金流率自由现金流/营收 | 352.8% | 21.0% |
| 资本支出强度资本支出/营收 | 32.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.55× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $5.2B | $509.4M |
8季度趋势，按日历期对齐
经营现金流BKRVTY
| Q4 25 | $5.2B | $182.0M | ||
| Q3 25 | $-1.1B | $138.5M | ||
| Q2 25 | $2.2B | $134.3M | ||
| Q1 25 | $412.0M | $128.2M | ||
| Q4 24 | $1.6B | $174.2M | ||
| Q3 24 | $-312.0M | $147.9M | ||
| Q2 24 | $2.1B | $158.6M | ||
| Q1 24 | $-2.7B | $147.6M |
自由现金流BKRVTY
| Q4 25 | $4.7B | $161.8M | ||
| Q3 25 | $-1.5B | $120.0M | ||
| Q2 25 | $1.8B | $115.5M | ||
| Q1 25 | $92.0M | $112.2M | ||
| Q4 24 | $1.1B | $149.8M | ||
| Q3 24 | $-687.0M | $125.6M | ||
| Q2 24 | $1.7B | $136.6M | ||
| Q1 24 | $-3.0B | $129.7M |
自由现金流率BKRVTY
| Q4 25 | 352.8% | 21.0% | ||
| Q3 25 | -121.5% | 17.2% | ||
| Q2 25 | 152.8% | 16.0% | ||
| Q1 25 | 7.9% | 16.9% | ||
| Q4 24 | 95.2% | 20.5% | ||
| Q3 24 | -65.6% | 18.4% | ||
| Q2 24 | 169.6% | 19.7% | ||
| Q1 24 | -286.4% | 20.0% |
资本支出强度BKRVTY
| Q4 25 | 32.4% | 2.6% | ||
| Q3 25 | 35.4% | 2.6% | ||
| Q2 25 | 29.8% | 2.6% | ||
| Q1 25 | 27.6% | 2.4% | ||
| Q4 24 | 34.6% | 3.4% | ||
| Q3 24 | 35.8% | 3.3% | ||
| Q2 24 | 37.1% | 3.2% | ||
| Q1 24 | 28.7% | 2.7% |
现金转化率BKRVTY
| Q4 25 | 3.55× | 1.85× | ||
| Q3 25 | -0.74× | 2.97× | ||
| Q2 25 | 1.54× | 2.49× | ||
| Q1 25 | 0.34× | 3.03× | ||
| Q4 24 | 1.34× | 1.84× | ||
| Q3 24 | -0.26× | 1.57× | ||
| Q2 24 | 1.82× | 2.87× | ||
| Q1 24 | -2.61× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BK
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
